November - 2024

top of page

Sage Group News

D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner

Our client, PolyPid Ltd. ( PolyPid - Optimized Therapeutics ; NASDAQ:PYPD) has a patented surgical site infection (SSI) prevention...

Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification

Evecxia deploys 5-hydroxytryptophan, 5-HTP, to achieve Serotonin Synthesis Amplification. 5-HTP amplifies brain serotonin and have shown...

bottom of page